JCR Pharmaceuticals Co (TSE:4552) ROCE % : 1.53% (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is JCR Pharmaceuticals Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. JCR Pharmaceuticals Co's annualized ROCE % for the quarter that ended in Dec. 2023 was 1.53%.

JCR Pharmaceuticals Co ROCE % Historical Data

The historical data trend for JCR Pharmaceuticals Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JCR Pharmaceuticals Co ROCE % Chart

JCR Pharmaceuticals Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

9.68

21.18

38.96

9.55

9.77

JCR Pharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															0.98	14.53	28.23	1.53	0.47

JCR Pharmaceuticals Co ROCE % Calculation

JCR Pharmaceuticals Co's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	7531	/	( ( (94937 - 35762)	+	(94937 - 0) )	/ 2 )
	=	7531	/	( (59175	+	94937)	/ 2 )
	=	7531	/	77056
	=	9.77 %

JCR Pharmaceuticals Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	1096	/	( ( (103988 - 31995)	+	(102773 - 31914) )	/ 2 )
	=	1096	/	( ( 71993	+	70859 )	/ 2 )
	=	1096	/	71426
	=	1.53 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

JCR Pharmaceuticals Co (TSE:4552) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

JCR Pharmaceuticals Co ROCE % Related Terms

Thank you for viewing the detailed overview of JCR Pharmaceuticals Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

JCR Pharmaceuticals Co (TSE:4552) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JCR Pharmaceuticals Co Ltd (TSE:4552) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

JCRRF:USA

Address

3-19 Kasuga-cho, Ashiya, Hyogo, JPN, 659-0021

Website

http://www.jcrpharm.co.jp

JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.

JCR Pharmaceuticals Co (TSE:4552) Headlines

No Headlines